Platelet membrane-coated drug delivery system
Disclosed herein is a platelet membrane-coated nanovehicle having an inner core comprising a drug delivery matrix, and an outer shell platelet membrane coating the inner core. The inner core can be any drug delivery matrix capable of delivering a therapeutic agent to a cell. The outer shell platelet membrane can be a natural or synthetic membrane comprising platelet proteins capable of interacting with cancer cells. Also disclosed is a method for treating cancer in a subject that involves administering to the subject a platelet membrane-coated nanovehicle disclosed herein. Also disclosed is a method for treating vascular disease in a subject that involves administering to the subject a platelet membrane-coated nanovehicle disclosed herein.
1. A platelet membrane-coated nanovehicle, comprising
a) an inner core comprising a drug delivery matrix, wherein the drug delivery matrix comprises an antineoplastic therapeutic agent; and
b) an outer shell platelet membrane coating the inner core, wherein the outer shell platelet membrane further comprises tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) and endogenous P-selectin protein.
2. The platelet membrane-coated nanovehicle of claim 1 , wherein the antineoplastic drug is a hydrophobic small molecule.
3. The platelet membrane-coated nanovehicle of claim 2 , wherein the anti-neoplastic drug is selected from the group consisting of paclitaxel, camptothecin, and docetaxel.
4. The platelet membrane-coated nanovehicle of claim 1 , wherein the antineoplastic drug is a hydrophilic small molecule.
5. The platelet membrane-coated nanovehicle of claim 1 , wherein the antineoplastic drug is selected from the group consisting of doxorubicin, cisplatin, and 5-fluorouracil.
6. The platelet membrane-coated nanovehicle of claim 1 , wherein the outer shell platelet membrane comprises integrin α IIb β 3 .
7. The platelet membrane-coated nanovehicle of claim 1 , wherein the outer shell platelet membrane comprises a self-recognized immunomodulatory protein selected from the group consisting of CD47, CD55, and CD59.
8. The platelet membrane-coated nanovehicle of claim 1 , wherein the outer shell platelet membrane further comprises a heterologous extracellularly active protein.
9. The platelet membrane-coated nanovehicle of claim 8 , wherein the extracellularly active protein comprises a therapeutic antibody.
10. The platelet membrane-coated nanovehicle of claim 9 , wherein the therapeutic antibody comprises cetuximab, trastuzumab, or a combination thereof.
11. The platelet membrane-coated nanovehicle of claim 1 , wherein the drug delivery matrix further comprises a polymeric gel.
12. The platelet membrane-coated nanovehicle of claim 1 , wherein the drug delivery matrix further comprises an inorganic particle.
13. The platelet membrane-coated nanovehicle of claim 1 , wherein the drug delivery matrix further comprises a lipid particle.
14. The platelet membrane-coated nanovehicle of claim 1 , wherein the drug delivery matrix further comprises a dendrimer particle.
15. A method comprising administering the platelet membrane-coated nanovehicle of claim 1 to a subject.
16. The method of claim 15 , wherein the subject is suffering from cancer.
17. The method of claim 15 , wherein the subject is suffering from a vascular disease.